ELORALINTIDE 5mg
$60.00
In stock (can be backordered)
SSL Secured
Secure Checkout
Guaranteed Delivery
Third-Party Tested
Eloralintide – Investigational Amylin Receptor Agonist
Eloralintide represents an emerging class of amylin-based metabolic research compounds. Its selective receptor activity and long-acting pharmacological profile make it a subject of interest in studies examining appetite regulation, energy homeostasis, and obesity-related metabolic pathways.
Early clinical investigations have evaluated its pharmacokinetics, tolerability, and effects on body weight, while additional research continues to examine its therapeutic potential.
Eloralintide – Investigational Amylin Receptor Agonist
Eloralintide (LY3841136) is a novel, long-acting, investigational peptide being studied for its potential role in metabolic regulation, appetite signaling, and body weight management. Developed by Eli Lilly, Eloralintide is a selective amylin receptor agonist designed to mimic the biological activity of amylin, a naturally occurring hormone involved in satiety, gastric emptying, and energy balance.
Unlike GLP-1 receptor agonists such as semaglutide and tirzepatide, Eloralintide targets the amylin signaling pathway, providing researchers with an alternative mechanism for investigating metabolic function and weight regulation.
Key Research Areas
-
Amylin Receptor Activation: Investigating selective amylin receptor signaling and its effects on metabolic pathways.
-
Appetite and Satiety Regulation: Studying mechanisms involved in hunger suppression, meal termination, and feelings of fullness.
-
Gastric Emptying: Exploring the influence of amylin signaling on gastrointestinal motility and nutrient processing.
-
Body Weight Regulation: Evaluating changes in body weight and energy intake in clinical research.
-
Combination Therapies: Investigating potential complementary effects when combined with GLP-1 receptor agonists and other metabolic research compounds.
Research Overview
Eloralintide represents an emerging class of amylin-based metabolic research compounds. Its selective receptor activity and long-acting pharmacological profile make it a subject of interest in studies examining appetite regulation, energy homeostasis, and obesity-related metabolic pathways.
Early clinical investigations have evaluated its pharmacokinetics, tolerability, and effects on body weight, while additional research continues to examine its therapeutic potential.
Classification: Selective Amylin Receptor Agonist Compound: Eloralintide (LY3841136) Research Category: Metabolic Research / Weight Regulation Development Status: Investigational
For Research Use Only (RUO). Not for human or veterinary use. Not approved by the FDA for therapeutic applications.
Product Specifications
Frequently Ask Questions
